Does intravitreal anti-VEGF treatment increase the risk of renal adverse events?
A review of the FDA’s Adverse Event Reporting System (FAERS) database found that there are no clear indications for the risk of renal adverse events (AEs) after treatment with intravitreal anti-VEGF drugs.
Researchers analyzed the time to onset, fatality, and hospitalization rates of renal AEs in patients treated with aflibercept, bevacizumab, ranibizumab, and brolucizumab from January 2004 to September 2022.
Over the study period, there were 80 reports, with a median time to AE of 37.5 days. In those who developed AEs, the hospitalization rate was 40.24% and the fatality rate was 9.76%.
Ranibizumab and aflibercept accounted for 46.25% and 42.50% of renal AEs respectively. However, the authors concluded that the association between intravitreal anti-VEGFs and renal AEs was insignificant.
Jiang L, Peng L, Zhou Y, et al. Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study. Front Med (Lausanne). 2023 Feb 14;10:1100397. doi: 10.3389/fmed.2023.1100397. PMID: 36865057; PMCID: PMC9972674.